首页> 外文期刊>Osteoarthritis and cartilage >Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis.
【24h】

Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis.

机译:血清寡聚基质蛋白(COMP)的血清水平与膝骨关节炎的影像学进展相关。

获取原文
获取原文并翻译 | 示例
           

摘要

Objective To evaluate the prognostic utility of serum COMP level measured with a new sandwich ELISA, by correlating COMP level with outcome measures of osteoarthritis (OA) progression.Design Patients (N=48) had symptomatic primary knee OA of Kellgren-Lawrence (K-L) grade I-III and met ACR criteria. These patients were evaluated prospectively as part of a double-blind drug trial of 3 years' duration and represented the placebo arm of the study. Serum COMP levels were measured by sandwich ELISA with monoclonal antibodies 16-F12 and 17-C10 at baseline and at study end and levels were correlated with changes in (1) joint space width (JSW), (2) K-L grade, (3) Lequesne, and (4) WOMAC indices, over 3 years.Results The change in JSW over 3 years, summed for both knees, correlated positively with serum COMP level at baseline as well as at study end. Patients were sorted by level of progression based upon a change in K-L grade summed for both knees over 3 years; patients who progressed by two K-L grades were shown to have had significantly higher COMP levels at baseline as well as at study end. Baseline and study end COMP levels did not correlate with the change of Lequesne or WOMAC indices. Baseline COMP levels correlated strongly with end serum COMP levels.Conclusion Serum COMP has the potential to be a prognostic marker of disease progression. High COMP levels, persisting over the 3-year study period in the patients with radiographic progression, indicated differences in disease activity detectable throughout the entire follow-up interval. Copyright 2002 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
机译:目的通过将COMP水平与骨关节炎(OA)进展的预后指标相关联,评估新的夹心ELISA法测定血清COMP水平的预后效用。设计患者(N = 48)有症状性原发性膝关节Kellgren-Lawrence(KL) I-III级并符合ACR标准。作为为期3年的双盲药物试验的一部分,对这些患者进行了前瞻性评估,并代表了研究的安慰剂组。在基线和研究结束时通过夹心ELISA和单克隆抗体16-F12和17-C10进行血清COMP水平测定,并将其水平与(1)关节间隙宽度(JSW),(2)KL级,(3)的变化相关Lequesne和(4)WOMAC指数超过3年。结果超过3年的JSW变化,包括两个膝盖的总和,与基线以及研究结束时的血清COMP水平呈正相关。根据3年中双膝总和的K-L等级变化按进展程度对患者进行分类。进展为两个K-L级的患者在基线以及研究结束时的COMP水平均显着提高。基线和研究结束时COMP水平与Lequesne或WOMAC指数的变化无关。基线COMP水平与最终血清COMP水平密切相关。结论血清COMP有可能成为疾病进展的预后指标。影像学进展患者在3年的研究期内一直保持较高的COMP水平,这表明在整个随访期间可检测到的疾病活动存在差异。版权所有2002 OsteoArthritis Research Society International。由Elsevier Science Ltd.出版。保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号